Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)

Publisher DOI
PubMed ID
22977195
Description
The EGF receptor (EGFR) is overexpressed in the majority of metastatic castration-resistant prostate cancers (mCRPC) and might represent a valid therapeutic target. The combination of docetaxel and cetuximab, the monoclonal antibody against EGFR, has not been tested in patients with prostate cancer.
Date of Publication
2012
Publication Type
Article
Language(s)
en
Contributor(s)
Cathomas, Richard
Rothermundt, Christian
Klingbiel, Dirk
Bubendorf, Lukas
Betticher, Daniel C
Brauchli, Peter
Cotting, Denise
Droege, Cornelia
Winterhalder, Ralph
Siciliano, Daniele
Berthold, Dominik R
Pless, Miklos
Schiess, Ralph
von Moos, Roger
Gillessen, Silke
Series
Clinical cancer research
Publisher
American Association for Cancer Research
ISSN
1078-0432
Access(Rights)
metadata.only
Show full item